Pharmacological treatment is the mainstay of care for patients with T2DM, particularly with the advent of newer antidiabetic drug classes such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor (GLP-1R) agonists, which have shown benefits in mitigating cardiovascular and renal complications. Here, SLC5A2 is linked to type 2 diabetes mellitus.